Implementation of Antimicrobial Stewardship Programs in End-of-Life Care
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Many terminal patients at the end-of-life have been receiving antimicrobial therapy despite concerns including futile use, potential lack of efficacy, increased patient burden, excess costs, high risk of adverse effects, and increased antimicrobial resistance. Thus, the implementation of antimicrobial stewardship programs (ASPs) in end-of-life care needs to be discussed. But, the topics of antimicrobial therapy and ASPs have not been addressed in the Life-Sustaining Treatment Decision Act enacted in the Korea in February 2016. Antimicrobial therapy should be included in the decision-making framework for end-of-life care similar to other life-sustaining treatment decisions. If the antimicrobial therapy is legally considered as a life-sustaining treatment which can be withdrawn or withheld in patients at the end-of-life, the feasibility of implementing ASPs among this patient population may improve. Various researches on antimicrobial therapy for patients at the end-of-life need to be conducted and collaborations are required between ASPs professionals and many other concerned parties involved in the legislative process of the Life-Sustaining Treatment Decision Act. This review aims to summarize previous studies on the use of antimicrobials for end-of-life care and reveal important aspects for applying ASPs to this population in Korea.
Abstract
Many terminal patients at the end-of-life have been receiving antimicrobial therapy despite concerns including futile use, potential lack of efficacy, increased patient burden, excess costs, high risk of adverse effects, and increased antimicrobial resistance. Thus, the implementation of antimicrobial stewardship programs (ASPs) in end-of-life care needs to be discussed. But, the topics of antimicrobial therapy and ASPs have not been addressed in the Life-Sustaining Treatment Decision Act enacted in the Korea in February 2016. Antimicrobial therapy should be included in the decision-making framework for end-of-life care similar to other life-sustaining treatment decisions. If the antimicrobial therapy is legally considered as a life-sustaining treatment which can be withdrawn or withheld in patients at the end-of-life, the feasibility of implementing ASPs among this patient population may improve. Various researches on antimicrobial therapy for patients at the end-of-life need to be conducted and collaborations are required between ASPs professionals and many other concerned parties involved in the legislative process of the Life-Sustaining Treatment Decision Act. This review aims to summarize previous studies on the use of antimicrobials for end-of-life care and reveal important aspects for applying ASPs to this population in Korea.
참고문헌 (33)
- "Hospice/palliative care and dying patient's decisions on life-sustaining treatment act (life-sustaining treatment decision act)"[URL]
- 이상민, "말기와 임종과정에 대한 정의 및 의학적 판단지침", 대한의사협회지, 61(8), pp.509~521 (2018), 대한의사협회[DOI]
- Oh DY, "Antibiotic use during the last days of life in cancer patients", Eur J Cancer Care(Engl), 15, pp.74~79 (2006)
- Kwak YG, "Frequent prescription of antibiotics and high burden of antibiotic resistance among deceased patients in general medical wards of acute care hospitals in Korea", PLoS One, 11, pp.e0146852~ (2016)
- Mitchell SL, "Infection management and multidrug-resistant organisms in nursing home residents with advanced dementia", JAMA Intern Med, 174, pp.1660~1667 (2014)
- Juthani-Mehta M, "Antimicrobials at the end of life : an opportunity to improve palliative care and infection management", JAMA, 314, pp.2017~2018 (2015)
- Yao CA, "Wishes of patients with terminal cancer and influencing factors toward the use of antibiotics in Taiwan", Am J Hosp Palliat Care, 32, pp.537~543 (2015)
- Marcus EL, "Ethical issues relating to the use of antimicrobial therapy in older adults", Clin Infect Dis, 33, pp.1697~1705 (2001)
- Society for Healthcare Epidemiology of America, "Policy statement on antimicrobial stewardship by the Society for Healthcare Epidemiology of America (SHEA), the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Diseases Society (PIDS)", Infect Control Hosp Epidemiol, 33, pp.322~327 (2012)
- Barlam TF, "Implementing an antibiotic stewardship program: guidelines by the infectious diseases society of America and the society for healthcare epidemiology of America", Clin Infect Dis, 62, pp.e51~e77 (2016)
- 김명희, "연명의료결정법의 문제점 및 개선 방안", Journal of Hospice and Palliative Care, 21(1), pp.1~8 (2018), 한국호스피스완화의료학회[DOI]
- 고윤석, "연명치료 중지에 관한 지침의 특징과 쟁점", 대한의사협회지, 54(7), pp.747~757 (2011), 대한의사협회
- "The white paper on the legalization of life-sustaining treatment decisions"[URL]
- "Monthly report of life-sustaining treatment decisions"[URL]
- Tagashira Y, "Antimicrobial prescribing in patients with advancedstage illness in the antimicrobial stewardship era", Infect Control Hosp Epidemiol, 39, pp.1023~1029 (2018)
- Dyer J, "Antimicrobial use in patients at the end of life in an Australian hospital", Infect Dis Health, 24, pp.92~97 (2019)
- 김현아, "심폐소생술금지 동의 전·후 말기암환자의 연명치료 변화", Journal of Hospice and Palliative Care, 20(2), pp.93~99 (2017), 한국호스피스완화의료학회[DOI]
- Baghban A, "Antimicrobial use at the end of life", Infect Dis Clin North Am, 31, pp.639~647 (2017)
- Datta R, "Burden and management of multidrug-resistant organisms in palliative care", Palliat Care, 10 (2017)
- Nakagawa S, "Can anti-infective drugs improve the infection-related symptoms of patients with cancer during the terminal stages of their lives?", J Palliat Med, 13, pp.535~540 (2010)
- Thompson AJ, "Antimicrobial use at the end of life among hospitalized patients with advanced cancer", Am J Hosp Palliat Care, 29, pp.599~603 (2012)
- Smits WK, "Clostridium difficile infection", Nat Rev Dis Primers, 2, pp.16020~ (2016)
- Levin PD, "End-of-life treatment and bacterial antibiotic resistance : a potential association", Chest, 138, pp.588~594 (2010)
- Sedef AM, "Procalcitonin as a biomarker for infection-related mortality in cancer patients", Curr Opin Support Palliat Care, 9, pp.168~173 (2015)
- Gaw CE, "Physician perceptions regarding antimicrobial use in end-of-life care", Infect Control Hosp Epidemiol, 39, pp.383~390 (2018)
- Rosenberg JH, "Antimicrobial use for symptom management in patients receiving hospice and palliative care : a systematic review", J Palliat Med, 16, pp.1568~1574 (2013)
- Albrecht JS, "A nationwide analysis of antibiotic use in hospice care in the final week of life", J Pain Symptom Manage, 46, pp.483~490 (2013)
- 고수진, "Experiences and Opinions Related to End-of-Life Discussion: From Oncologists' and Resident Physicians' Perspectives", Cancer Research and Treatment, 50(2), pp.614~623 (2018), 대한암학회
- White PH, "Antimicrobial use in patients with advanced cancer receiving hospice care", J Pain Symptom Manage, 25, pp.438~443 (2003)
- Yun YH, "Attitudes of cancer patients, family caregivers, oncologists and members of the general public toward critical interventions at the end of life of terminally ill patients", CMAJ, 183, pp.E673~E679 (2011)
- 고수진, "Attitudes and Opinions of Elderly Patients and Family Caregivers on End-of-Life Care Discussion", Annals of geriatric medicine and research, 21(2), pp.49~55 (2017), 대한노인병학회[DOI]
- Broom J, "Why is optimisation of antimicrobial use difficult at the end of life?", Intern Med J, 49, pp.269~271 (2019)
- Abdel-Karim IA, "Causes of death at autopsy in an inpatient hospice program", J Palliat Med, 10, pp.894~898 (2007)